CTLA4 and melanoma: Historically, advanced melanoma has a poor prognosis, with a 5-year survival rate of less than 10%.1 Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 have shown improved survival in advanced melanoma patients1–4, but only a subset of patients respond.